These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30951880)

  • 1. Symptomatic HIV CNS viral escape among patients on effective cART.
    Manesh A; Barnabas R; Mani S; Karthik R; Abraham OC; Chacko G; Kannangai R; Varghese GM
    Int J Infect Dis; 2019 Jul; 84():39-43. PubMed ID: 30951880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy.
    Donath M; Wolf T; Stürmer M; Herrmann E; Bickel M; Khaykin P; Göpel S; Gute P; Haberl A; de Leuw P; Schüttfort G; Berger A; Stephan C;
    Med Microbiol Immunol; 2016 Dec; 205(6):575-583. PubMed ID: 27469377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Learning from cerebrospinal fluid drug-resistant HIV escape-associated encephalitis: a case report.
    Kang J; Wang Z; Zhou Y; Wang W; Wen Y
    Virol J; 2023 Dec; 20(1):292. PubMed ID: 38072961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
    Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression.
    Imaz A; Cayuela N; Niubó J; Tiraboschi JM; Izquierdo C; Cabellos C; Podzamczer D
    AIDS Res Hum Retroviruses; 2014 Oct; 30(10):984-7. PubMed ID: 25096495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity.
    Lescure FX; Moulignier A; Savatovsky J; Amiel C; Carcelain G; Molina JM; Gallien S; Pacanovski J; Pialoux G; Adle-Biassette H; Gray F
    Clin Infect Dis; 2013 Jul; 57(1):101-8. PubMed ID: 23515205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.
    Rokx C; Gras L; van de Vijver D; Verbon A; Rijnders B;
    HIV Med; 2016 Sep; 17(8):571-80. PubMed ID: 26842457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
    Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
    Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
    Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
    Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals.
    De Luca A; Ciancio BC; Larussa D; Murri R; Cingolani A; Rizzo MG; Giancola ML; Ammassari A; Ortona L
    Neurology; 2002 Aug; 59(3):342-7. PubMed ID: 12177366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy.
    Lin KY; Liao SH; Liu WC; Cheng A; Lin SW; Chang SY; Tsai MS; Kuo CH; Wu MR; Wang HP; Hung CC; Chang SC
    PLoS One; 2015; 10(9):e0137660. PubMed ID: 26360703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
    Santos JR; Moltó J; Llibre JM; Pérez N; Capitán ; Miranda C; Clotet B
    HIV Clin Trials; 2009; 10(3):129-34. PubMed ID: 19632951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptomatic cerebrospinal fluid escape.
    Mastrangelo A; Turrini F; de Zan V; Caccia R; Gerevini S; Cinque P
    AIDS; 2019 Dec; 33 Suppl 2():S159-S169. PubMed ID: 31789816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive Impairment and Persistent CNS Injury in Treated HIV.
    Chan P; Hellmuth J; Spudich S; Valcour V
    Curr HIV/AIDS Rep; 2016 Aug; 13(4):209-17. PubMed ID: 27188299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.